RecruitingNCT05619068

The Evolution and Prognosis of Moyamoya Disease

Imaging Investigation on the Evolution and Prognosis of Moyamoya Disease


Sponsor

Chinese PLA General Hospital

Enrollment

300 participants

Start Date

Sep 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

To investigate the evolution of imaging appearances and cognitive function of Moyamoya disease (MMD) and to establish a prognosis evaluation system based on imaging biomarkers in MMD. The study may be helpful to optimize and improve the diagnosis and pretreatment assessment of MMD, and provide an important theoretical supplement to the existing guidelines for the management of MMD.


Eligibility

Min Age: 10 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cognitive impairment, functional impairment, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05619068


Related Trials